On the morning of April 17 in Hanoi, the Ministry of Health officially announced a high-level personnel decision for the country’s leading pharmaceutical quality control agency.
Appointment Details: According to Decision No. 868/QD-BYT, Assoc. Prof. Dr. Doan Cao Son has been re-appointed to the position of Director of the National Institute of Drug Quality Control (NIDQC). The term of office is five years, effective from April 1, 2026.
Assessment and Expectations: During the previous term, the institution successfully monitored the market, maintaining a low rate of substandard and counterfeit drugs compared to regional levels. For the new term, the Ministry of Health has outlined five key objectives for the Institute’s management board:
-
Systemic Strategy: Finalizing the project to enhance national testing capacity immediately after the general planning is approved.
-
Professional Standing: Maintaining international-standard technical capabilities to serve as the backbone for drug and cosmetic quality supervision.
-
Organizational Improvement: Focusing on high-level expert training and talent recruitment to facilitate international integration.
-
Science and Technology: Promoting research, modern technical transfers, and comprehensive digitalization of management processes.
-
Work Environment: Ensuring transparency, democracy, and improving the well-being of the staff.
Upon accepting the appointment, Assoc. Prof. Dr. Doan Cao Son pledged to collaborate with the medical staff to focus on innovation and digital transformation to meet quality control demands amidst increasingly complex pharmaceutical market fluctuations.